Replimune Group Balance Sheet Health
Financial Health criteria checks 5/6
Replimune Group has a total shareholder equity of $421.5M and total debt of $44.4M, which brings its debt-to-equity ratio to 10.5%. Its total assets and total liabilities are $532.9M and $111.4M respectively.
Key information
10.5%
Debt to equity ratio
US$44.43m
Debt
| Interest coverage ratio | n/a |
| Cash | US$466.35m |
| Equity | US$421.54m |
| Total liabilities | US$111.39m |
| Total assets | US$532.93m |
Recent financial health updates
Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Feb 06
Is Replimune Group (NASDAQ:REPL) A Risky Investment?
Jul 13Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?
Apr 05Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Aug 06We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate
Apr 04Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth
Dec 16Recent updates
Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Feb 06Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer
Jan 23Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)
Dec 25Is Replimune Group (NASDAQ:REPL) A Risky Investment?
Jul 13Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?
Apr 05A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)
Jan 06Replimune secures $200M term loan
Oct 07Replimune: Recent Developments Strengthen Bull Thesis
Aug 12Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Aug 06Replimune Group GAAP EPS of -$0.78 misses by $0.15
Aug 04Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate
Jun 24We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate
Apr 04Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth
Dec 16Replimune: In The 'Buy Zone' Again
Oct 01Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)
Sep 02Replimune Group (NASDAQ:REPL) Is In A Strong Position To Grow Its Business
May 24Replimune: Oncolytic Immunotherapy Pioneer Gaining Momentum In The Clinic
Apr 30We're Interested To See How Replimune Group (NASDAQ:REPL) Uses Its Cash Hoard To Grow
Feb 08Replimune Group EPS misses by $0.03
Feb 04Dosing underway in Replimune's early-stage cancer study with gene therapy
Jan 05Replimune: Interesting Developer Of Oncolytic Immunotherapies
Dec 06Replimune Group EPS misses by $0.02
Nov 05Financial Position Analysis
Short Term Liabilities: REPL's short term assets ($479.2M) exceed its short term liabilities ($38.7M).
Long Term Liabilities: REPL's short term assets ($479.2M) exceed its long term liabilities ($72.7M).
Debt to Equity History and Analysis
Debt Level: REPL has more cash than its total debt.
Reducing Debt: REPL's debt to equity ratio has increased from 0% to 10.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: REPL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: REPL has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 32.4% each year.